MRNA Stock Chart & Stats
$947.00
-$48.00(-4.82%)
At close: 4:00 PM EDT
$947.00
-$48.00(-4.82%)
Day’s Range― - ―
52-Week Range$414.00 - $1,451.38
Previous CloseN/A
Volume179.00
Average Volume (3M)1.18K
Market Cap
$375.15B
Enterprise Value$16.16K
Total Cash (Recent Filing)$1.72B
Total Debt (Recent Filing)$1.24B
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding396,786,250
10 Day Avg. Volume335
30 Day Avg. Volume1,177
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$834.19Price Target Upside-11.91% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-150.44
Revenue Forecast (FY)$36.35B
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength And Low LeverageModerna's low-to-moderate leverage and multi‑billion dollar cash position provide durable financial flexibility to fund multi-year R&D, manufacturing scale-up and global launches. This solvency supports investment in pipeline programs even if commercial revenues remain lumpy over the next 2–6 months.
Demonstrated Cost Discipline And Lower Cash CostsA sustained 26% YoY reduction in adjusted cash costs reflects structural rightsizing of operating expenses and tighter expense management. Lower recurring cash costs improve the odds of reaching adjusted profitability, lengthen runway, and reduce the reliance on financing while backing late‑stage program investments.
Broader Infectious Disease Portfolio And Regulatory ProgressMultiple approvals and filings expand Moderna's commercial franchise beyond Spikevax, diversifying revenue sources and strengthening commercial channels. A pipeline of respiratory and other approved products creates a more resilient revenue base and supports longer‑term adoption across geographies and seasons.
Bears Say
Large Litigation Settlement And Contingent Legal ExposureThe settlement materially raised cost of sales and GAAP losses, creating a persistent legal overhang and potential multi‑year liability. Even if classified as non‑recurring, the payout reduces cash available for ops and adds uncertainty to free cash flow and earnings recovery over the next several quarters.
Negative Operating And Free Cash Flow With Expected Cash DrawdownPersistent negative operating/free cash flow and a planned drawdown to ~$4.5–$5.0B by year‑end indicate Moderna must fund continued R&D and commercialization from reserves. This reduces financial flexibility and raises the probability of future financing or cutbacks if revenue and margin recovery slow.
Weak Core Profitability And Margin StructureDeep negative gross and net margins signal the business' cost base is still misaligned with post‑pandemic revenue levels. Until sustained top‑line growth or structural margin improvement occurs, Moderna will struggle to generate self‑funding profits and rebuild shareholder equity over the medium term.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $414.00 and its highest was $1451.38 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $375.15B.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 29, 2026 which is in 90 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -$34.182 earnings per share for the quarter, beating the consensus estimate of -$35.084 by $0.902.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moderna have?
Moderna has 396,786,250 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$34.182 in its last earnings report, beating expectations of -$35.084. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MX:MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$834.19 (-11.91% Downside)
$834.19 (-11.91% Downside)
Blogger Sentiment
Bullish
MX:MRNA Sentiment 73%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $433.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly constructive commercial and scientific update: strong Q1 revenue growth (driven by international strategic partnerships), multiple regulatory approvals (including the first flu+COVID combo), meaningful cost reductions (adjusted cash cost down 26% YoY) and continued pipeline advancement across respiratory, oncology and rare diseases. Offsetting these positives were a large, near-term litigation settlement charge recognized in Q1 that materially increased cost of sales and GAAP loss, potential contingent legal exposure (up to $1.3B) with multi‑year timing uncertainty, and expected cash drawdown through 2026. On balance, the company demonstrated operational execution and long‑term value drivers while managing a significant one‑time legal headwind.View all MX:MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$834.19
▼(-11.91% Downside)